Abstract
Twenty consecutive patients with unresectable, locally advanced pancreatic cancer were treated with split courses of radiotherapy (RT) and simultaneous multidrug chemotherapy consisting of 5 fluorouracil, continuous infusion, streptozotocin, and cisplatin. A separate, retrospective study identified a group of 28 contemporary patients with less advanced pancreatic cancers, all of which were successfully resected. The survival rate of the two groups were similar over the first 2 years, although it initially favored the unresectable group. This pattern of survival among patients treated with combined modality therapy provides a basis for new studies. At the two clinical extremes, these include treatment of unrespectable tumors previously considered ineligible for this treatment and initial treatment before resection of stage I tumors.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 199-203 |
| Number of pages | 5 |
| Journal | Journal of clinical gastroenterology |
| Volume | 16 |
| Issue number | 3 |
| DOIs | |
| State | Published - Apr 1993 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- 5-Fluorouracil
- Chemotherapy
- Cisplatin
- Combined modality therapy
- Pancreatic cancer
- Radiotherapy
- Streptozotocin
ASJC Scopus subject areas
- Gastroenterology
Fingerprint
Dive into the research topics of 'Survival after combined modality therapy for pancreatic cancer'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS